SOTHEMA (CAS:SOT) YoY EBITDA Growth: 6.42% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAS:SOT SOTHEMA CAS:SOT
71 GF Score
Price MAD368.00
GF Value MAD289.33
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is SOTHEMA YoY EBITDA Growth?

SOTHEMA CAS:SOT +0.14% 71 YoY EBITDA Growth is 6.42% as of Dec. 2025. GuruFocus rates CAS:SOT with a GF Score™ of 71/100 and a GF Value™ of MAD289.33 (Modestly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. SOTHEMA's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 6.42%.

SOTHEMA's EBITDA per Share for the six months ended in Dec. 2025 was MAD9.37.

SOTHEMA YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for SOTHEMA's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SOTHEMA YoY EBITDA Growth Chart

SOTHEMA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.43 2.57 -3.63 27.69 14.39

SOTHEMA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.79 -1.50 54.16 21.15 6.42
CAS:SOT
71GF Score
SOTHEMA CAS:SOT
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SOTHEMA YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

SOTHEMA's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(19.023-16.63)/ | 16.63 |
=14.39 %

SOTHEMA's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(9.372-8.807)/ | 8.807 |
=6.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 6.42% mean?
SOTHEMA (CAS:SOT) has a YoY EBITDA Growth of 6.42% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SOTHEMA and its competitors.
Is SOTHEMA's YoY EBITDA Growth too high?
SOTHEMA's current YoY EBITDA Growth is 6.42%. Overall, SOTHEMA has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's YoY EBITDA Growth compare to LLY and JNJ?
SOTHEMA's YoY EBITDA Growth of 6.42% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for SOTHEMA and its competitors. SOTHEMA's current YoY EBITDA Growth is 6.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Modestly Overvalued. The stock's GF Value™ is MAD289.33, compared to a current price of MAD368.00 — trading 27.2% above its estimated fair value. The current YoY EBITDA Growth is 6.42%. SOTHEMA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current YoY EBITDA Growth is 6.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SOTHEMA (CAS:SOT) Overvalued in 2026?

Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued. The current stock price of MAD368.00 is trading 27.2% above its estimated GF Value™ of MAD289.33. GuruFocus considers SOTHEMA to be Modestly Overvalued.

Key valuation signals for CAS:SOT:

  • YoY EBITDA Growth: 6.42%
  • GF Value™: MAD289.33 vs. price of MAD368.00 (27.2% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SOTHEMA Business Description

Address Centre de Bouskoura, BP no. 1, Casablanca, MAR
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
71GF Score

Get the complete analysis for CAS:SOT

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD368.00
Price
MAD289.33
GF Value